Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies.

ABSTRACT: Digestive tumours, a common kind of malignancy worldwide, have recently led to the most tumour-related deaths. Angiogenesis, the process of forming novel blood vessels from pre-existing vessels, is involved in various physiological and pathological processes in the body. Many studies suggest that abnormal angiogenesis plays an important role in the growth, progression, and metastasis of digestive tumours. Therefore, anti-angiogenic therapy is considered a promising target for improving therapeutic efficacy. Traditional strategies such as bevacizumab and regorafenib can target and block the activity of proangiogenic factors to treat digestive tumours. However, due to resistance and some limitations, such as poor pharmacokinetics, their efficacy is not always satisfactory. In recent years, n

SUBMITTER: Yang Z 

PROVIDER: S-EPMC8784389 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature